Join the 'Avodart' group to help and get support from people like you.

Avodart Blog

Drug May Slow Early Prostate Cancer: Study

Posted 24 Jan 2012 by Drugs.com

TUESDAY, Jan. 24 – New research suggests that Avodart, a drug used to treat an enlarged prostate gland, may help slow the progression of early stage prostate cancer, reducing the need for aggressive treatment in some men. Prostate cancer can grow and spread slowly, which is why some men are urged to engage in so-called watchful waiting when the cancer is first diagnosed. Avodart (dutasteride) may help such men feel comfortable with surveillance as opposed to radical treatment, the researchers noted. "The concept of active surveillance is gaining traction in most parts of the world," said study author Dr. Neil E. Fleshner, head of the division of urology at the Princess Margaret Hospital in Toronto. Still, some men are uncomfortable with doing nothing in the face of a cancer diagnosis, he said. "By using this drug, we can improve the proportion of men who remain committed to the ... Read more

Related support groups: Prostate Cancer, Benign Prostatic Hyperplasia (BPH), Avodart, Dutasteride

FDA OKs Impotence Drug Cialis to Treat Enlarged Prostate

Posted 7 Oct 2011 by Drugs.com

THURSDAY, Oct. 6 – The U.S. Food and Drug Administration announced late Thursday that it had approved using the erectile dysfunction drug Cialis as a treatment for enlarged prostate. According to the U.S. National Institutes of Health, enlarged prostate – clinically known as benign prostatic hyperplasia (BPH) – is a "common part of aging" for men. In fact, the NIH estimates that "more than half of men in their 60s, and as many as 90 percent in their 70s and 80s, have some symptoms of BPH." The condition often leads to urinary incontinence and can raise the odds for urinary tract infections and even kidney damage. "BPH can have a big impact on a patient's quality of life," Scott Monroe, director of the division of reproductive and urologic products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "A large number of older men have symptoms of BPH. ... Read more

Related support groups: Erectile Dysfunction, Cialis, Flomax, Benign Prostatic Hyperplasia (BPH), Urinary Incontinence, Avodart, Rapaflo, Cardura, Jalyn, Proscar, Hytrin, Uroxatral

Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer

Posted 9 Jun 2011 by Drugs.com

THURSDAY, June 9 – The U.S. Food and Drug Administration is calling for new warning labels on a class of drugs used primarily to treat enlarged prostates, because the medications may raise the risk of developing an aggressive form of prostate cancer. In a statement released Thursday, the agency said the drugs involved include popular medications sold under the brand names Proscar and Propecia (sold by Merck & Co.) and Avodart and Jalyn (sold by GlaxoSmithKline). According to the FDA, almost 5 million men were prescribed one of these medications between 2002 and 2009. Of these, nearly 3 million men were between the ages of 50 and 79. The agency is advising doctors not to start patients on these drugs until prostate cancer – which can mimic the symptoms of an enlarged prostate – and other urological conditions have been ruled out. According to the agency, this new warning is based on ... Read more

Related support groups: Avodart, Finasteride, Jalyn, Propecia, Proscar, Dutasteride, Dutasteride/tamsulosin

FDA Medwatch Alert: 5-alpha reductase inhibitors (5-ARIs): Label Change - Increased Risk of Prostate Cancer

Posted 9 Jun 2011 by Drugs.com

Drugs in the 5-ARI class include finasteride and dutasteride. These drugs are marketed under the brand-names Proscar, Propecia, Avodart, and Jalyn ISSUE: FDA notified healthcare professionals that the Warnings and Precautions section of the labels for the 5-alpha reductase inhibitor (5-ARI) class of drugs has been revised to include new safety information about the increased risk of being diagnosed with a more serious form of prostate cancer (high-grade prostate cancer). BACKGROUND: The new safety information is based on FDA’s review of two large, randomized controlled trials––the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Proscar, Avodart, and Jalyn are approved to improve symptoms of an enlarged prostate gland (benign prostatic hyperplasia or BPH). Proscar and Avodart are also approved to reduce the risk of urina ... Read more

Related support groups: Avodart, Finasteride, Jalyn, Propecia, Proscar, Dutasteride, Dutasteride/tamsulosin

Sexual Side Effects From Propecia, Avodart May Be Irreversible

Posted 10 Mar 2011 by Drugs.com

THURSDAY, March 10 – Drugs frequently prescribed to treat hair loss or an enlarged prostate may contribute to irreversible sexual dysfunction in men, new research finds. Use of dutasteride (Avodart) and finasteride (Proscar and Propecia) were linked to erectile dysfunction, depression and loss of libido in a review of existing studies. In a small percentage of cases, symptoms persisted even after the medication was stopped. For those men, "it's a life sentence," said lead researcher Abdulmaged M. Traish, a professor of biochemistry and urology at Boston University School of Medicine. "No sex. No desire. Potential depression," Traish added. Almost everyone who takes these drugs experiences some of these side effects, Traish said. "But, some experience it more drastically than others," he added. The drugs – prescribed to treat a common urological condition called benign prostatic ... Read more

Related support groups: Avodart, Finasteride, Propecia, Proscar, Dutasteride

FDA Panel to Vote on Drugs to Prevent Prostate Cancer

Posted 1 Dec 2010 by Drugs.com

WEDNESDAY, Dec. 1 – A U.S. Food and Drug Administration advisory panel is expected to decide Wednesday whether to approve two drugs for the prevention of prostate cancer, the third highest cancer killer of men. Avodart and Proscar, manufactured by GlaxoSmithKline and Merck, respectively, are already approved to treat enlarged prostates. The drug makers say their research shows the drugs also lower the risk of prostate cancer by more than 20 percent. FDA regulators have several concerns, the Associated Press reported. For one thing, black men, who are at high risk for the disease, were underrepresented in the clinical trials. "The applicability to African-American men is not known due to marked under-representation," the FDA's online review stated. Blacks made up just 4 percent of Merck's patients and only 2 percent of Glaxo's patients, according to the AP. The panel of outside experts ... Read more

Related support groups: Prostate Cancer, Avodart, Proscar

Study Revives Debate on Prostate Drug

Posted 2 Apr 2010 by Drugs.com

WEDNESDAY, March 31 – A new study to determine whether a drug prescribed to fight the problems of an enlarged prostate gland can also reduce the risk of prostate cancer promises to prolong a debate that started with an earlier study of a similar drug. The renewed debate plays out in the April 1 issue of the New England Journal of Medicine, which carries not only a report saying that the drug dutasteride (Avodart) may reduce the risk for prostate cancer but also an editorial that counters the upbeat conclusions of the study point by point. The results of the four-year study of the effect of Avodart on prostate – financed by Glaxo, which markets the drug – seem to mirror those of a 19,000-participant study in 2003 of finasteride (Propecia), which found a 25 percent lower incidence of prostate cancer among men who took that drug than among those who took a placebo. But that study has ... Read more

Related support groups: Avodart, Finasteride, Propecia, Proscar, Dutasteride

Prostate Meds Not Tied to Increased Hip Fracture Risk

Posted 7 Oct 2008 by Drugs.com

TUESDAY, Oct. 7 – A new study found no link between the use of a drug to treat an enlarged prostate and an increase in hip fractures in men. The study, published in the Oct. 8 issue of the Journal of the American Medical Association, does not completely clear the class of medications known as 5-a reductase inhibitors, because it did not find out how the drugs affect long-term bone health. The inhibitors, such as finasteride and dutasteride, are a first-line treatment for an enlarged prostate – a condition called benign prostatic hyperplasia, or BPH, which is common in older men. It has been estimated that more than 8 million American men age 50 to 79 years will meet the current guidelines for considering treatment options for BPH by 2010, according to background information in the article. The new study included 7,076 men, 45 years old and older, who suffered a hip fracture between ... Read more

Related support groups: Avodart, Propecia

Ask a Question

Further Information

Related Condition Support Groups

Benign Prostatic Hyperplasia (BPH)

Avodart Patient Information at Drugs.com